Selected research
Industry Research
Lipid Nanoparticle (LNP) Formulation Industry Research Report 2026
Market perspective
The global Lipid Nanoparticle (LNP) Formulation market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lipid Nanoparticle (LNP) Formulation market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lipid Nanoparticle (LNP) Formulation market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lipid Nanoparticle (LNP) Formulation market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lipid Nanoparticle (LNP) Formulation include Precision NanoSystems (Cytiva), Ascendia Pharmaceuticals, CordenPharma, Evonik, Merck Millipore, Esco Aster, WuXi STA and Helix Biotech, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lipid Nanoparticle (LNP) Formulation market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lipid Nanoparticle (LNP) Formulation.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lipid Nanoparticle (LNP) Formulation Market by Company
Precision NanoSystems (Cytiva)
Ascendia Pharmaceuticals
CordenPharma
Evonik
Merck Millipore
Esco Aster
WuXi STA
Helix Biotech
Lipid Nanoparticle (LNP) Formulation Segment by Type
mRNA-lipid Nanoparticle
siRNA-lipid Nanoparticle
Lipid Nanoparticle (LNP) Formulation Segment by Application
In Vitro and In Vivo Diagnostics
Medical Imaging
Nanotherapeutics
Vaccines
Regenerative Medicine
Lipid Nanoparticle (LNP) Formulation Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid Nanoparticle (LNP) Formulation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lipid Nanoparticle (LNP) Formulation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid Nanoparticle (LNP) Formulation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lipid Nanoparticle (LNP) Formulation companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA-lipid Nanoparticle
- siRNA-lipid Nanoparticle
Applications
- In Vitro and In Vivo Diagnostics
- Medical Imaging
- Nanotherapeutics
- Vaccines
- Regenerative Medicine
Companies covered
- Precision NanoSystems (Cytiva)
- Ascendia Pharmaceuticals
- CordenPharma
- Evonik
- Merck Millipore
- Esco Aster
- WuXi STA
- Helix Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lipid Nanoparticle (LNP) Formulation by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 mRNA-lipid Nanoparticle
- 2.2.3 siRNA-lipid Nanoparticle
- 2.3 Lipid Nanoparticle (LNP) Formulation by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 In Vitro and In Vivo Diagnostics
- 2.3.3 Medical Imaging
- 2.3.4 Nanotherapeutics
- 2.3.5 Vaccines
- 2.3.6 Regenerative Medicine
- 2.4 Assumptions and Limitations
3 Lipid Nanoparticle (LNP) Formulation Breakdown Data by Type
- 3.1 Global Lipid Nanoparticle (LNP) Formulation Historic Market Size by Type (2021-2026)
- 3.2 Global Lipid Nanoparticle (LNP) Formulation Forecasted Market Size by Type (2027-2032)
4 Lipid Nanoparticle (LNP) Formulation Breakdown Data by Application
- 4.1 Global Lipid Nanoparticle (LNP) Formulation Historic Market Size by Application (2021-2026)
- 4.2 Global Lipid Nanoparticle (LNP) Formulation Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lipid Nanoparticle (LNP) Formulation Market Perspective (2021-2032)
- 5.2 Global Lipid Nanoparticle (LNP) Formulation Growth Trends by Region
- 5.2.1 Global Lipid Nanoparticle (LNP) Formulation Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lipid Nanoparticle (LNP) Formulation Historic Market Size by Region (2021-2026)
- 5.2.3 Lipid Nanoparticle (LNP) Formulation Forecasted Market Size by Region (2027-2032)
- 5.3 Lipid Nanoparticle (LNP) Formulation Market Dynamics
- 5.3.1 Lipid Nanoparticle (LNP) Formulation Industry Trends
- 5.3.2 Lipid Nanoparticle (LNP) Formulation Market Drivers
- 5.3.3 Lipid Nanoparticle (LNP) Formulation Market Challenges
- 5.3.4 Lipid Nanoparticle (LNP) Formulation Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lipid Nanoparticle (LNP) Formulation Players by Revenue
- 6.1.1 Global Top Lipid Nanoparticle (LNP) Formulation Players by Revenue (2021-2026)
- 6.1.2 Global Lipid Nanoparticle (LNP) Formulation Revenue Market Share by Players (2021-2026)
- 6.2 Global Lipid Nanoparticle (LNP) Formulation Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lipid Nanoparticle (LNP) Formulation Head Office and Area Served
- 6.4 Global Lipid Nanoparticle (LNP) Formulation Players, Product Type & Application
- 6.5 Global Lipid Nanoparticle (LNP) Formulation Manufacturers Established Date
- 6.6 Global Lipid Nanoparticle (LNP) Formulation Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lipid Nanoparticle (LNP) Formulation Market Size (2021-2032)
- 7.2 North America Lipid Nanoparticle (LNP) Formulation Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lipid Nanoparticle (LNP) Formulation Market Size by Country (2021-2026)
- 7.4 North America Lipid Nanoparticle (LNP) Formulation Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lipid Nanoparticle (LNP) Formulation Market Size (2021-2032)
- 8.2 Europe Lipid Nanoparticle (LNP) Formulation Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lipid Nanoparticle (LNP) Formulation Market Size by Country (2021-2026)
- 8.4 Europe Lipid Nanoparticle (LNP) Formulation Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Market Size (2021-2032)
- 9.2 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lipid Nanoparticle (LNP) Formulation Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lipid Nanoparticle (LNP) Formulation Market Size (2021-2032)
- 10.2 South America Lipid Nanoparticle (LNP) Formulation Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lipid Nanoparticle (LNP) Formulation Market Size by Country (2021-2026)
- 10.4 South America Lipid Nanoparticle (LNP) Formulation Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Market Size (2021-2032)
- 11.2 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lipid Nanoparticle (LNP) Formulation Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Precision NanoSystems (Cytiva)
- 12.1.1 Precision NanoSystems (Cytiva) Company Information
- 12.1.2 Precision NanoSystems (Cytiva) Business Overview
- 12.1.3 Precision NanoSystems (Cytiva) Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.1.4 Precision NanoSystems (Cytiva) Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.1.5 Precision NanoSystems (Cytiva) Recent Developments
- 12.2 Ascendia Pharmaceuticals
- 12.2.1 Ascendia Pharmaceuticals Company Information
- 12.2.2 Ascendia Pharmaceuticals Business Overview
- 12.2.3 Ascendia Pharmaceuticals Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.2.4 Ascendia Pharmaceuticals Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.2.5 Ascendia Pharmaceuticals Recent Developments
- 12.3 CordenPharma
- 12.3.1 CordenPharma Company Information
- 12.3.2 CordenPharma Business Overview
- 12.3.3 CordenPharma Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.3.4 CordenPharma Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.3.5 CordenPharma Recent Developments
- 12.4 Evonik
- 12.4.1 Evonik Company Information
- 12.4.2 Evonik Business Overview
- 12.4.3 Evonik Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.4.4 Evonik Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.4.5 Evonik Recent Developments
- 12.5 Merck Millipore
- 12.5.1 Merck Millipore Company Information
- 12.5.2 Merck Millipore Business Overview
- 12.5.3 Merck Millipore Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.5.4 Merck Millipore Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.5.5 Merck Millipore Recent Developments
- 12.6 Esco Aster
- 12.6.1 Esco Aster Company Information
- 12.6.2 Esco Aster Business Overview
- 12.6.3 Esco Aster Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.6.4 Esco Aster Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.6.5 Esco Aster Recent Developments
- 12.7 WuXi STA
- 12.7.1 WuXi STA Company Information
- 12.7.2 WuXi STA Business Overview
- 12.7.3 WuXi STA Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.7.4 WuXi STA Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.7.5 WuXi STA Recent Developments
- 12.8 Helix Biotech
- 12.8.1 Helix Biotech Company Information
- 12.8.2 Helix Biotech Business Overview
- 12.8.3 Helix Biotech Revenue in Lipid Nanoparticle (LNP) Formulation Business (2021-2026)
- 12.8.4 Helix Biotech Lipid Nanoparticle (LNP) Formulation Product Portfolio
- 12.8.5 Helix Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst